Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation
Le Wang(Beijing University of Chinese Medicine), Hing L. Sham(University of Nottingham Ningbo China), Jang Y. Lee(Abbott Fund), Robert B. Warner(Abbott Fund), Nicolette Zielinski-Mozng(Abbott Fund), Steven M. Hannick(Abbott Fund), Kenneth J. Barr(Abbott Fund), R.B. Credo(Abbott Fund), Richard W. McCroskey(Abbott Fund), Laura Gherke(Abbott Fund), Qun Li(Sichuan University), Saul H. Rosenberg(Abbott Fund), David J. Frost(Abbott Fund), Kennan Marsh(Abbott Fund), Yu-Hua Hui(Abbott Fund), Keith W. Woods(Abbott Fund)
Cited by 421
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k